• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?

作者信息

Dintsios Charalabos-Markos, Chernyak Nadja

机构信息

Institute for Health Services Research and Health Economics, Medical Faculty, Heinrich Heine University, Building 17.11, Moorenstr. 5, 40225, Düsseldorf, Germany.

出版信息

Appl Health Econ Health Policy. 2022 May;20(3):287-290. doi: 10.1007/s40258-021-00712-x. Epub 2021 Dec 29.

DOI:10.1007/s40258-021-00712-x
PMID:34964091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9021141/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0cc/9021141/eca017c09069/40258_2021_712_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0cc/9021141/eca017c09069/40258_2021_712_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0cc/9021141/eca017c09069/40258_2021_712_Fig1_HTML.jpg

相似文献

1
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?在德国医保改革法案（AMNOG）实施十年后，德国距离基于价值的定价还有多远？
Appl Health Econ Health Policy. 2022 May;20(3):287-290. doi: 10.1007/s40258-021-00712-x. Epub 2021 Dec 29.
2
Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.德国药品价格监管对抗癌药物定价影响的经验教训
Health Aff (Millwood). 2020 Jul;39(7):1185-1193. doi: 10.1377/hlthaff.2019.01122.
3
Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?德国的药品定价：在加速审批程序（AMNOG）范围内价值是如何确定的？
Value Health. 2017 Jul-Aug;20(7):927-935. doi: 10.1016/j.jval.2017.04.006. Epub 2017 May 16.
4
Predictors of negotiated prices for new drugs in Germany.德国新药谈判价格的预测因素。
Eur J Health Econ. 2020 Sep;21(7):1049-1057. doi: 10.1007/s10198-020-01201-z. Epub 2020 May 25.
5
[Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].[德国医疗卫生技术评估体系（AMNOG）下的效益评估与价格谈判：可计算的过程还是不公平的博弈？]
Gesundheitswesen. 2018 Jun;80(6):573-579. doi: 10.1055/s-0042-113600. Epub 2016 Sep 16.
6
[The costs of new drugs compared to current standard treatment].[新药与现行标准治疗方法的成本比较]
Z Evid Fortbild Qual Gesundhwes. 2013;107(7):461-7. doi: 10.1016/j.zefq.2013.04.031. Epub 2013 May 31.
7
[Analysis of Late AMNOG Benefit Assessments].[晚期德国医疗卫生技术评估机构（AMNOG）效益评估分析]
Gesundheitswesen. 2018 Aug;80(8-09):e44-e53. doi: 10.1055/a-0592-6725. Epub 2018 Apr 26.
8
Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.德国的参考定价：对美国药品采购的影响。
Issue Brief (Commonw Fund). 2019 Feb 1;2019:1-8.
9
Consequences of implementing a drug budget for office-based physicians in Germany.在德国为门诊医生实施药品预算的后果。
Pharmacoeconomics. 1996;10 Suppl 2:37-47. doi: 10.2165/00019053-199600102-00007.
10
[The German Pharmaceutical Market Reorganization Act (AMNOG) from an economic point of view].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):291-7. doi: 10.1007/s00103-014-2116-z.

引用本文的文献

1
Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review.关于潜在创新型卫生技术的价格决定因素及定价政策：一项范围综述
Eur J Health Econ. 2025 Sep 6. doi: 10.1007/s10198-025-01834-y.
2
Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally.激励新型抗生素和诊断试剂进入市场的定价、采购和报销政策：全球 10 个国家的经验教训。
Appl Health Econ Health Policy. 2024 Sep;22(5):629-652. doi: 10.1007/s40258-024-00888-y. Epub 2024 Jun 5.

本文引用的文献

1
International Experience in Therapeutic Value and Value-Based Pricing: A Rapid Review of the Literature.国际治疗价值和基于价值的定价经验：文献快速综述。
Value Health Reg Issues. 2020 Dec;23:37-48. doi: 10.1016/j.vhri.2019.11.008. Epub 2020 Jul 17.
2
Predictors of negotiated prices for new drugs in Germany.德国新药谈判价格的预测因素。
Eur J Health Econ. 2020 Sep;21(7):1049-1057. doi: 10.1007/s10198-020-01201-z. Epub 2020 May 25.
3
Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan.
药品和医疗器械的成本效益评估：日本新的基于价值的价格调整体系。
Int J Technol Assess Health Care. 2020 Jun;36(3):270-276. doi: 10.1017/S0266462320000264. Epub 2020 May 18.
4
Implementation of Value-based Pricing for Medicines.药品基于价值的定价实施。
Clin Ther. 2020 Jan;42(1):15-24. doi: 10.1016/j.clinthera.2019.11.006. Epub 2019 Dec 24.
5
Does external reference pricing deliver what it promises? Evidence on its impact at national level.外部参考定价能否如其承诺的那样发挥作用？国家层面的影响证据。
Eur J Health Econ. 2020 Feb;21(1):129-151. doi: 10.1007/s10198-019-01116-4. Epub 2019 Oct 3.
6
"Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.德国在药品市场改革后对药品的“市场撤药”：卫生技术评估评级与临床指南建议的比较
Health Econ Rev. 2018 Sep 18;8(1):23. doi: 10.1186/s13561-018-0209-3.
7
Value judgment of health interventions from different perspectives: arguments and criteria.从不同视角对健康干预措施的价值判断：论据与标准
Cost Eff Resour Alloc. 2018 Apr 17;16:16. doi: 10.1186/s12962-018-0099-6. eCollection 2018.
8
Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.德国医保支付方与制药商价格谈判失败时确定药品创新报销金额的仲裁委员会：基于五年经验的实证分析
Value Health. 2016 Dec;19(8):1016-1025. doi: 10.1016/j.jval.2016.05.016. Epub 2016 Jul 15.
9
Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach.为进行获益评估而对患者亚组进行询问：对德国联邦联合委员会的方法提出质疑。
Value Health. 2014 Jun;17(4):307-9. doi: 10.1016/j.jval.2014.05.001.
10
Approaches to identifying, measuring, and aggregating elements of value.识别、衡量和汇总价值要素的方法。
Int J Technol Assess Health Care. 2013 Oct;29(4):360-4. doi: 10.1017/S0266462313000524.